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Abstract: Nonalcoholic fatty liver disease (NAFLD) pathogenesis is explained by the complex relationship 
among diet and lifestyle-predisposing factors, the genetic variance of the nuclear and mitochondrial 
genome, associated phenotypic traits, and the yet not fully explored interactions with epigenetic and other 
environmental factors, including the microbiome. Despite the wealth of knowledge gained from molecular 
and genome-wide investigations in patients with NAFLD, the precise mechanisms that explain the variability 
of the histological phenotypes are not fully understood. Earlier studies of the gut microbiota in patients with 
NAFLD and nonalcoholic steatohepatitis (NASH) provided clues on the role of the fecal microbiome in 
the disease pathogenesis. Nevertheless, the composition of the gut microbiota does not fully explain tissue-
specific mechanisms associated with the degree of disease severity, including liver inflammation, ballooning 
of hepatocytes, and fibrosis. The liver acts as a key filtration system of the whole body by receiving blood 
from the hepatic artery and the portal vein. Therefore, not only microbes would become entrapped in the 
complex liver anatomy but, more importantly, bacterial derived products that are likely to be potentially 
powerful stimuli for initiating the inflammatory response. Hence, the study of liver tissue microbiota offers 
the opportunity of changing the paradigm of host-NAFLD-microbial interactions from a “gut-centric” to 
a “liver-centric” approach. Here, we highlight the evidence on the role of liver tissue bacterial DNA in the 
biology of NAFLD and NASH. Besides, we provide evidence of metagenomic findings that can serve as the 
seed of further hypothesis-raising studies as well as can be leveraged to discover novel therapeutic targets.
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Nonalcoholic fatty liver disease (NAFLD) pathogenesis 
is explained by the complex relationship among diet and 
lifestyle-predisposing factors, genetic variance of the nuclear 
and mitochondrial genome, special characteristics of the 
phenome, including obesity, and the yet not fully explored 
interactions with epigenetic and other environmental 
factors, including the microbiome (1).
Despite the wealth of knowledge gained from molecular 
and genome-wide investigations in patients with NAFLD, 
the precise mechanisms that explain the variability of the 
histological phenotypes are not fully understood (2,3). 
Earlier studies on the gut microbiota in patients with 
NAFLD and nonalcoholic steatohepatitis (NASH) provided 
clues on the feces bacterial profile/s associated with the 
disease (4-19) (Figure 1). Nevertheless, the composition 
of the gut microbiota does not fully explain tissue-specific 
mechanisms associated with the degree of disease severity, 
including liver inflammation, ballooning of hepatocytes, and 
fibrosis. Here, we highlight the evidence on the role of liver 
tissue bacterial DNA in the biology of NAFLD and NASH. 
Besides, we provide evidence of metagenomic findings that 
can serve as the seed of further hypothesis-raising studies 
as well as can be leveraged to discover novel therapeutic 
targets.
Non-intestinal microbiotas and liver diseases
With the explosion of  knowledge in the f ie ld of 
metagenomics, novel concepts on the pathogenesis of 
complex diseases emerged, including the putative role of 
tissue microbiotas.
A remarkable seminal study that surveyed bacteria profiles 
from up to 27 different body sites from healthy adults over 
time found that bacterial composition is primarily determined 
by the body habitat (20). This study demonstrated that the 
human microbiota varies systematically across body habitats, 
and it has thus established the basis onto which to explore 
tissue microbiotas in different disease states (20).
Explorations from studies in the past decade, particularly 
in the field of cardiovascular disease, suggested that the 
microbial composition of non-intestinal tissues may 
contribute to the pathogenesis of non-transmissible complex 
diseases. For example, Koren et al. used pyrosequencing 
of 16S rRNA genes to survey the bacterial diversity of 
atherosclerotic plaques and identified Chryseomonas in 
all atherosclerotic plaque samples, and Veillonella and 
Streptococcus in the majority (21). More recently, explorations 
of the microbiome in the circulating compartment showed 
that an increase in the proportion of Proteobacteria phylum 
would predict long-term cardiovascular prognosis (22). The 
putative role of the blood microbiome in the pathogenesis 
of other diseases, particularly inflammatory diseases, is 
beyond the scope of this review and it has been thoroughly 
reviewed before (23).
Notably, emerging studies in the field of liver diseases 
demonstrated the importance of the non-intestinal 
microbiotas in the development and/or the prognosis of 
different disease states, from metabolic, inflammatory, and 
autoimmune diseases to cancer.
These studies involved the profiling of the microbiome 
of a wide range of non-intestinal biological sources, from 
samples of the peripheral blood to bile acid and bile duct 
tissue, saliva, and, more recently, the liver tissue (Figure 2). 
These investigations lead to important discoveries that 
generated new hypotheses on host-bacterial interactions. 
For instance, Puri and coworkers investigated the 
circulating microbiome signature in patients with alcoholic 
hepatitis and found that the relative abundance of the 
phylum Bacteroidetes was significantly decreased in alcohol-
consuming patients (24). In addition, the circulating 
microbiome of subjects consuming alcohol was significantly 
enriched with the gram-negative bacilli phylum Fusobacteria 
and its subclasses Fusobacteriales and Leptotrichiaceae (24).
Cho et al. explored the blood microbiome of patients 
with cirrhosis and hepatocellular carcinoma (HCC) and 
found that Staphylococcus, Acinetobacter, Klebsiella, and 
Trabulsiella were significantly enriched in HCC-associated 
microbiomes (25).
Lelouvier et al. investigated the relationship between the 
blood microbiota and liver fibrosis in European cohorts of 
patients with severe obesity and observed that changes in 
several taxa correlated with the fibrosis status, including the 
genera Sphingomonas, Bosea, and Variovorax (26).
Kajihara and coworkers examined the peripheral blood 
microbiota of patients with liver cirrhosis by 16S rRNA 
gene sequencing and found that while the abundance of 
Enterobacteriaceae was significantly increased, the abundance 
of Akkermansia, Rikenellaceae and Erysipelotrichales was 
decreased in cirrhotic patients (27).
Zhang et al. evaluated the blood microbiome in patients 
with hepatitis B-related acute-on-chronic liver failure and 
found that that the relative abundance of Prevotellaceae 
independently predicted 28-day mortality (28).
On the other hand, there were interesting studies 
focused on the examination of the microbiome profile 
of bile acid and/or bile duct tissue samples. For example, 
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Figure 1 Summary of human studies of gut microbiota in NAFLD and NASH (4-19). NAFLD, nonalcoholic fatty liver disease; NASH, 
nonalcoholic steatohepatitis; CHD, coronary heart disease; HCC, hepatocellular carcinoma.
Chng and coworkers found that several bacterial families 
with a significant increase in Stenotrophomonas species 
allowed for distinguishing tumors vs. paired non-tumors 
samples in patients with cholangiocarcinoma (29). Pereira 
et al. collected bile samples from the common bile duct in 
patients at different stages of primary sclerosing cholangitis 
and found that Streptococcus abundance was positively 
correlated with an increase in the disease severity (30).
Based on the profiling of salivary microbiota, Bajaj 
and coworkers (31) reported that salivary dysbiosis was 
greater in patients with cirrhosis who developed 90-day 
hospitalizations because of hepatic encephalopathy.
Finally, we have explored the liver tissue bacterial DNA 
profile in patients with NAFLD and different phenotypic 
and histological characteristics and found for the first 
time that the liver tissue of NAFLD patients contains a 
diverse repertoire of bacterial DNA (up to 2.5×104 read 
counts) (32). More importantly, we observed that the liver 
metataxonomic signature may explain differences in the 
NAFLD pathogenic mechanisms as well as physiological 
functions of the host (32).
Biogeography of the liver tissue bacterial DNA of 
patients with NAFLD
The liver acts as a key filtration system of the whole body by 
receiving blood from the hepatic artery and the portal vein. 
Therefore, not only microbes would become entrapped in 
the complex liver anatomy but, more importantly, bacterial-
derived products that are likely to be potentially powerful 
stimuli for initiating the inflammatory response.
Trans loca t ion  o f  bac ter i a l  product s  f rom the 
gastrointestinal tract to the liver is largely acknowledged as 
implicated in the complications of liver cirrhosis (33). More 
recently, the existence of crosstalk between microbes and 
host liver cells that control metabolism has been proposed 
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Figure 2 Summary of studies on non-intestinal microbiotas in diverse liver diseases (24-31). HCC, hepatocellular carcinoma.
to explain not only de novo hepatic lipogenesis that occurs 
in NAFLD but also associated liver damage as elegantly 
reviewed by Tilg et al. (34).
We have profiled the liver tissue microbial DNA in 
patients with NAFLD and different histological stages (32). 
Regarding the biogeography of the bacterial DNA found 
in the liver tissue specimens, we found that the hepatic 
microbiome profile reflects bacterial DNA communities 
that can be found not only across the entire gastrointestinal 
tract—from the oral cavity to the distal colon—but also 
bacterial DNA potentially derived of other body sites 
(Figure 3). For example, while we found that many 
bacterial DNA in the liver tissue samples of patients with 
NAFLD have been previously reported as microorganisms 
that inhabit the human intestinal tract, for example, 
Bifidobacterium , Peptostreptococcus , Stenotrophomonas , 
Xanthomonadaceae, Lachnoclostridium, and Ruminococcaceae—
among many other taxa (35), we observed bacterial DNA 
potentially derived from other body sites as well. For 
example, we found that Deinococcus Thermus, which is 
recognized as one of the most extremophilic phyla of 
Bacteria (36), was distinctively overabundant in the liver of 
non-morbidly obese patients with NAFLD (32). Deinococcus 
Thermus species represent a fraction of the bacterial 
communities residing in the human stomach (37), which is 
known for its acidic and inhospitable environment. These 
results might suggest the potential source of liver bacterial 
DNA that could migrate from the stomach to the liver. 
Also, this result might suggest the possibility of different 
stress-related tissue environments in different cohorts of 
patients, for example oxidative and/or metabolic stress 
(38-40),  which would, in turn modulate bacterial 
communities’ adaptation and survival.
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bacterial DNA might be derived from the oral microbiome (41), 
for example, Actinobacteria and Prevotella, and some species 
of Deltaproteobacteria.
Other features deserve particular attention. For example, 
we found the presence of bacterial DNA of Gemella genus 
in patients with higher scores of portal inflammation (32). 
Gemella is abundant in the proximal small intestine, and some 
species of this genus, for instance, Gemella spp can translocate 
to other organs and thus cause systemic diseases (42).
Likewise, we found that the abundance of bacterial DNA 
of Peptostreptococcus was significantly increased in the liver of 
morbidly obese patients with NASH (32). The presence in 
the gut of members of the Peptostreptococcaceae family is often 
associated with compromised health, for instance, elderly 
hospitalized patients with Clostridium difficile infection 
exposed to previous antibiotic (43), ulcerative colitis (44), 
and colorectal cancer (45).
Microbiota or bacterial DNA can have negative and 
positive effects on the host. For instance, we found that 
depletion of DNA from Lachnospiraceae family members was 
particularly associated with severe histological features (32). 
Several members of the Lachnospiraceae family are butyrate 
producers; microbial butyrate-producing communities are 
often reported as associated with the healthy microbiota.
Besides, microbiota-derived butyrate presumably 
presents several health benefits. For example, butyrate is 
able to beneficially affect oxidative stress in the healthy 
human colon (46), it might have anti-proliferative effects 
by interfering with prostaglandin E2 synthesis (47), and 
butyrate may modulate immunological homeostasis in the 
gut (48). The decrease in butyrate from gut bacteria has 
been also linked to energy imbalance and disturbances in 
body weight and glucose control (49).
A recent experimental study showed that Lachnospiraceae 
administration attenuates obesity, inflammation, and 
dysbiosis (50). It has been also reported diminution of 
Lachnospiraceae microbial populations in patients with 
inflammatory bowel diseases (51). Remarkably, a human 
study showed that gut microbial function, inflammation, 
and cognition were markedly improved in cirrhotic patients 
by capsular fecal transplant containing Lachnospiraceae (52).
Furthermore, we found that overabundance of DNA 
derived from gram-negative Proteobacteria, particularly 
Gammaproteobacteria, was a distinguishing feature of NASH 
and NASH-related severe histological outcomes (32). 
For example, DNA derived from Stenotrophomonas was 
3.1-fold increased in the liver of morbidly obese patients 
with NASH. Likewise, DNA derived from Xanthomonadaceae 
family members was consistently increased in all NASH 
patients regardless of their body mass index status (32). We 
Figure 3 Summary of biogeography of bacterial DNA found in the liver tissue of patients with NAFLD. Summary indicates results of the 
study of Sookoian et al. (32). NAFLD, nonalcoholic fatty liver disease.
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also found that DNA from Alpha and Gamma Proteobacteria 
was consistently associated with increased lobular and portal 
inflammation scores (32).
Concurrently, we demonstrated not only that the 
liver tissue of NASH patients contains DNA from 
Gammaproteobacteria but we found that lipopolysaccharide 
(LPS)—the major component of the outer membrane in 
gram-negative bacterial pathogens, predominantly localized 
in the portal tracts (32).
Bacterial DNA induces inflammatory response
Bacterial DNA is not immunologically inert. Quite the 
opposite, bacterial DNA is sensed by the immune system as 
a signal of infectious danger mostly because the structure of 
bacterial DNA presents high frequency of the dinucleotides 
CG and lacks of methylation (53).
Interactions between bacterial derived products, 
inc lud ing  bac ter ia l  DNA and  RNA induce  hos t 
inflammatory responses by activating the innate immune 
defense system, including the inflammasome (54). 
Activation of innate immune system in response of highly 
conserved microbial structures is known as pathogen-
associated molecular patterns (PAMPs) (55). Collectively, 
these findings suggest that bacterial DNA itself may 
be a significant microbial mediator of inflammation in 
affected tissues by stimulating pro-inflammatory cytokine 
production, including interferon factor alpha (IFNα) (53) 
and tumor necrosis factor alpha (TNFα) (56), priming 
of the inflammasome (57,58), and activation of toll like 
receptors (59).
Advances in genomics and bioinformatics revealed 
that bacterial DNA might potentially integrate into the 
human genome through an RNA intermediate and such 
integrations are detected more frequently in tumor than 
normal cells (60). This finding not only transforms current 
knowledge of host-bacterial-interactions but also opens 
new avenues of research in the field of NASH and the 
development of HCC, particularly in non-cirrhotic patients.
Bacteria-bacteria interactions are another interesting 
mechanism to explain pathogen-host  effects .  We 
hypothesized that differences in liver bacterial DNA 
diversity between cohorts of NAFLD patients with 
different phenotypic features, including severely obese 
versus moderate obese patients, would also reflect putative 
differences in systemic ecological diversity. We thus 
performed network analysis of bacterial DNA communities, 
and observed that bacterial DNA found in the liver of 
morbidly obese patients with NAFLD clustered separately 
from the bacterial DNA of the liver of NAFLD-non-
morbidly obese patients. More importantly, while clusters 
of bacterial DNA communities presented significant 
intra-cluster positive correlations, significant negative co-
occurrences between clusters were observed, for example 
between Gammaproteobacteria and Lachnospiraceae, which 
were precisely linked to severe and benign histological 
phenotypes, respectively (Figure 4); this pattern was 
replicated at all taxonomic levels.
Liver tissue metagenomic findings can be 
leveraged to identify therapeutic targets against 
NASH
The putative interplay between the liver tissue cellular 
components and bacteria-derived products has never been 
explored before in humans. A rodent study that investigated 
ethanol-associated compositional microbiome changes 
along the intestinal tract and the liver showed that ethanol 
increases bacterial richness in the jejunum and changed 
bacterial communities in the ileum by inducing a shift 
towards gram-negative bacteria (61).
As mentioned in the preceding paragraphs, we have 
shown that the presence of bacterial DNA in the liver 
tissue of patients with NAFLD would be implicated as a 
contributing factor in the disease pathogenesis (32).
Microbiome and host genetics are often explored as 
independent contributing factors in complex disorders, 
albeit there is a clear and biologically plausible interplay 
between these two factors. It becomes then obvious that 
understanding the putative synergistic effect/s between 
the microbiome and/or its byproducts and the genetic 
background of the host may serve to predict and design 
novel personalized treatments. The goal would be to 
identify novel pathways and interactions with microbial 
components that could provide effective therapies for 
NASH. Nevertheless, there are gaps in our understanding 
of how and which of these putative interactions between 
the tissue microbiota and the host-genetics impact on the 
disease biology.
Recently, a study by Abul-Husn et al. revealed that 
rs72613567, a loss-of-function variation in HSD17B13 
(17-beta-hydroxysteroid dehydrogenase 13) gene, confers 
protection against chronic liver injury and mitigates the 
progression of NAFLD and alcoholic liver disease in 
European Americans (62). We further replicated these 
findings and demonstrated that the rs72613567 A-INS allele 
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Figure 4 Network analysis of liver bacterial DNA communities and their interactions. Network analysis for identifying co-occurring 
bacteria, mutually exclusive bacteria, and clusters of co-occurring bacteria was performed by the Calypso online software (http://cgenome.
net/wiki/index.php/Calypso). Co-occurrences were calculated by Spearman’s rho; thus, different taxa, which are represented by nodes, and 
positive and negative correlations are shown in the network. Network analysis was performed at the OTU level (top 1,000 most abundant 
taxa) (A) and family level (B) for bacterial DNA communities residing in the liver of morbidly obese (yellow nodes) and non-morbidly obese 
(green nodes) subjects with NAFLD (32). The network plot shows co-occurring and mutually exclusive bacteria. Each node represents 
an OUT or family (a and b, respectively), and each edge represents a significant pairwise association between them. Taxon abundance is 
represented as node size. Nodes are placed by PCoA and are connected via edges based on Spearman’s rho correlations, signifying positive 
(red lines) and negative (blue lines) associations. Correlations (presented as edges) are subsequently sorted for adjusted (FDR) statistical 
significance (P<0.05) and R>±0.6. NAFLD, nonalcoholic fatty liver disease.
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protects against NAFLD [odds ratio (OR) per adenine allele 
=0.667; 95% CI, 0.486–0.916; P=0.012] (63). In addition, 
we found that the A-INS allele protects against NASH 
(OR =0.612; 95% CI, 0.388–0.964), ballooning degeneration 
(OR =0.474; 95% CI, 0.267–0.842), lobular inflammation 
(OR =0.475; 95% CI, 0.275–0.821), and fibrosis (OR =0.590; 
95% CI, 0.361–0.965) (63). Subsequent studies from other 
groups (64-67) found similar results. Importantly, as shown 
by immunohistochemistry, there was a dose-dependent 
decreasing effect of the rs72613567 A-INS on the expression 
levels of the HSD17B13 protein in the liver (63).
Notably, we have performed the liver transcriptome 
analysis of NAFLD patients carrying the rs72613567 
(–/–) homozygous genotype versus the reference group 
[rs72613567 (A/A) homozygous genotype], and we found 
that the most (≥3.5-fold) downregulated and upregulated 
genes in the liver of patients carrying the rs72613567 (–/–) 
genotype were in biological pathways related to the immune 
system, including antigen presentation and interferon-
related processes, as well as cytokine signaling (63). 
Accordingly, previous evidence from experimental studies 
showed that hydroxysteroid (17 beta) dehydrogenase 13 
deficiency triggers hepatic steatosis and inflammation in 
mice (68). Together, these observations raised the possibility 
that therapeutic inhibition of HSD17B13 could represent a 
new strategy to treat NASH patients with more severe liver 
histology (1,63,69).
HSD17B13 as a hydroxysteroid dehydrogenase (HSD) 
belongs to the superfamily of short-chain dehydrogenases/
reductases (SDR); these enzymes are involved in the 
steroid hormone metabolism among others. Disruption in 
the signaling of members of the SDR family may cause a 
wide range of inflammatory diseases, from hypertension to 
cancer  (70) .  Likewise ,  the  metabol ic  act iv i ty  of 
microorganisms co-inhabiting the human body, particularly 
the gut, may act as a parallel endocrine site by producing 
hormones that can interfere with human physiology. For 
example, it has been long speculated that the composition 
of the gastrointestinal microbiota may be involved in the 
development of cancer (71). Also, interference with steroid 
hormone metabolism, e.g., progesterone, estradiol and 
cortisol, may affect the inflammatory response (72).
Hence, it was speculated about a possible relationship 
between host-genetics and microbiota that would modulate 
the inflammatory response through to the activity of steroid 
metabolism, and this relationship might alternatively affect 
bile acid signaling as well (70).
Meanwhile, it remains to be explored whether the 
rs72613567 variant in HSD17B13 presents any direct or 
indirect interaction effect with the microbial composition 
of the body, including the liver or bile acid bacterial 
composition, which might explain in part the missing 
heritability of NAFLD and NASH (1). Unfortunately, 
knowledge of the function and regulation of HSD17B13 
is still missing; no crystal structure was deposited in the 
protein database (PDB) for HSD17B13 either. Therefore, 
criteria for exploration of HSD17B13 druggability 
predictions are currently inconclusive. Conversely, 
HSD17B11 (estradiol 17-beta-dehydrogenase 11)—
a protein of the same family that HSD17B13, has been 
largely studied (Figure 5A). HSD17B13 shares ~65% of its 
amino acid sequence with HSD17B11 (E value: 1.3e–131) 
being the closest family member (Figure 5B), and similarly 
to HSD17B13, HSD17B11 is located in the endoplasmic 
reticulum. As a proof-of-concept, we modeled the putative 
druggability (the ability of a binding site to bind a drug-
like ligand) of HSD17B11 to demonstrate the potentiality 
of targeting HSD17B13. Together, the analysis of available 
HSD17B11 protein structure was straightforward suggesting 
that proteins in the same family, including HSD17B13, 
are predicted to be druggable (Figure 5C,D). Analysis 
of structural ligandability of HSD17B11 (Figure 5C,D) 
shows a binding site conformation with a putative pocket 
for binding small drugs.
Variants in many other candidate genes remain 
unexplored, for example rs59846192 in DMRTB1 (DMRT 
like family B with proline rich C-terminal 1) that has been 
associated with relative abundance of Lachnospira in earlier 
studies (73).
Nevertheless, the most relevant message is that microbial 
associations with host-genome variants are body site-specific 
(74). Hence, associations of host-genome variants with the 
fecal microbiome do not necessarily explain the effect of 
liver tissue microbial and host-genetics interactions.
Areas of future research
An important yet poorly explored aspect of the microbial 
and host-genetics interactions is the possibility of drug-
metabolizing proteins encoded by the microbiome genes 
might interfere with patients’ response to medicinal drugs. 
There is evidence from recent literature that intestinal 
metagenomic abundance of bacterial phyla, genera, 
species, and their gene products are able to interfere with 
many drugs used to treat human diseases, for instance 
norethindrone acetate and famciclovir (75). A study 
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that combined genomics of human gut commensals and 
gnotobiotic animal experiments to quantify microbiota and 
host contributions to drug metabolism provided remarkable 
evidence on the microbiome drug-metabolizing activity (76). 
The model consisted of eight compartments, including 
three sections of the small intestine, three sections of the 
large intestine, gallbladder, and a central compartment, 
representing processes occurring in serum, liver and 
other tissues (76). This investigation demonstrated that 
while bacterial drug conversion influences both intestinal 
and systemic drug metabolite levels, the main factors 
affecting systemic drug metabolite levels were systemic 
Figure 5 Homolog-based druggability prediction of HSD17B13. (A) Radar plot (illumination graph) depicting the variety of knowledge on 
HSD17B11 and HSD17B13 obtained by Pharos (Pharos NIH Druggable Genome Knowledgebase available at https://pharos.nih.gov/). The 
radar chart is a visualization of gene-attribute associations; this radial plot summarizes the level of accumulated knowledge about both genes/
proteins above mentioned. The further the point is away from the center of the radial plot, the more knowledge exists about the target. 
Knowledge value: 0 to 1 scale. HSD17B11: most knowledge about: PubMed ID: 0.86, small molecule perturbation: 0.83, transcription factor 
binding site profil: 0.8, gene perturbation: 0.74, tissue sample: 0.71. HSD17B13: most knowledge about cell type or tissue: 0.68, microRNA: 
0.58, tissue sample: 0.53, cell line: 0.45, chemical: 0.44; (B) family cladogram based on network proteins of the short-chain dehydrogenases/
reductases (SDR) family. The graph shows human HSD17B11 and HSD17B13 as the closest linked members. (https://cansarblack.icr.ac.uk); 
(C) structural ligandability of HSD17B11 by X-ray diffraction (https://cansarblack.icr.ac.uk); (D) “bindability” of HSD17B11 protein: 
predicted binding site pocket suggests high chances of binding of small molecules with high affinity. (https://cansarblack.icr.ac.uk).
HSD17B11: Estradiol 17-beta-dehydrogenase 11
Molecular function: oxidoreductase
Biological process: lipid biosysthesis; lipid metabolism; steroid biosynthesis.
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metabolite elimination and biliary secretion rates of the 
drug (76). Surprisingly, drug metabolites produced by 
the gut microbiota substantially contributed to systemic 
exposure (76). It remains to be explored whether tissular 
metataxonomic profiles represent microbiotas. Tissular 
microbiotas, in particular the liver, might affect drug 
pharmacokinetics, possessing potential implications in novel 
discoveries for the treatment of NASH. Deciphering the 
interrelationship between liver tissular microbiota and anti-
NASH drugs pharmacokinetics and pharmacodynamics 
would be a breakthrough in the understanding of 
interpersonal variability in drug response.
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